Definitive Contract 75N93022C00019

The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...

The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,272,000.00 Firm Fixed Price, Definitive Contract to Zymeron Corporation, a minority-owned, for-profit biotechnology company. The contract is for the development of "Rapid Point of Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood" under the Small Business Innovation Research (SBIR) Program Phase II. This research aligns with the...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, to develop rapid point-of-care tests to simultaneously quantify anti-tuberculosis drugs in blood. The $299,920 contract, awarded on August 26, 2019, supports research and development to advance innovative diagnostics and...

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000.00 firm-fixed-price definitive contract to Zymeron Corporation, a minority-owned small business, to provide rapid point-of-care tests to quantify hepatitis C virus. The contract has an estimated completion date of August 30, 2022 and was awarded on August 31, 2021. Zymeron is a research-based biotechnology company that develops innovative technologies...

Zymeron Corporation has been awarded a $300,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to deliver an orodispersible film formulation of a second line drug for pediatric tuberculosis treatment. The contract is set aside for total small businesses and will be completed by August 31, 2022. Performance will take place in Durham, North Carolina. This award supports the National Institute of Allergy and...

This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...

Zymeron Corporation was awarded a $400,000 firm fixed price definitive contract by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to develop user-friendly technologies and devices to create an at-home Hepatitis C virus test under the Small Business Innovation Research Program Topic 441. As a small business concern, Zymeron will conduct the research and development effort at its facilities in Research Triangle Park, North Carolina through...

This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...

This contract is a $249,999.09 Small Business Innovation Research (SBIR) Phase I award from the Department of the Army Medical Command to Zymeron Corporation, a minority-owned biotechnology company based in Research Triangle Park, North Carolina. The award supports the research and development of a "Novel Antibiotic Targeting Multidrug-Resistant Pseudomonas Aeruginosa Infections." As a prime contractor, Zymeron has experience providing medical research, engineering services, IT...

This is a firm-fixed-price purchase order contract awarded by the U.S. Army Research, Development and Engineering Command (RDECOM) to Zymeron Corporation, a minority-owned, for-profit biotechnology company, under the Small Business Innovation Research (SBIR) Program Phase I. The contract, valued at $197,000.00, is for research and development services related to an unspecified biomedical or public health initiative. As a total small business set-aside, this award aligns with Zymeron's...